Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2019; 19(3):166-171
DOI: 10.5428/pcar20190303
Research progress in clinical treatment of oral anticoagulants
1. MENG Lu1(1.Graduate School,Hebei Medical University,Shijiazhuang 050017,China 2311136730@qq.com)
2. DING Congyang1(1.Graduate School,Hebei Medical University,Shijiazhuang 050017,China )
3. AN Jing1(1.Graduate School,Hebei Medical University,Shijiazhuang 050017,China )
4. 2( 2.Department of Pharmacy,Hebei General Hospital,Shijiazhuang 050051,China )
5. LI Yajing1(1.Graduate School,Hebei Medical University,Shijiazhuang 050017,China )
6. LI Ying2( 2.Department of Pharmacy,Hebei General Hospital,Shijiazhuang 050051,China )
7. DONG Zhanjun1(1.Graduate School,Hebei Medical University,Shijiazhuang 050017,China 13313213656@126.com)
8. 2( 2.Department of Pharmacy,Hebei General Hospital,Shijiazhuang 050051,China )
ABSTRACT   In recent years,with the increasing incidence and mortality of thromboembolic diseases,anticoagulants have important clinical significance and practical value to the prevention and treatment of thromboembolic diseases.Oral anticoagulants are mainly divided into traditional oral drugs and new oral anticoagulants.Clinically,warfarin is commonly used as a traditional oral anticoagulant.However,its treatment window is narrow,dosage needs constantly adjustment,and the interactions between warfarin and other drugs and food bring about inconvenience in clinical use.New oral anticoagulants,such as rivaroxaban,apisaban,edoxaban,betroxaban and dabigatran etexilate,are superior to warfarin,because of the advantages of no frequent dosage adjustment,no routine monitoring of coagulation function and low bleeding rate in the treatment of thrombotic diseases.Besides,their safety and efficacy are by no means inferior to warfarin.This article reviews related literature on the progress of drug therapy for thromboembolic diseases published at home and abroad in recent years,and provides references for the standardized use of oral anticoagulants in clinical practice.
Welcome to PCAR! You are the number 41 reader of this article!
Please cite this article as:
MENG Lu1,DING Congyang1,AN Jing1,2,LI Yajing1,LI Ying2,DONG Zhanjun1,2,. Research progress in clinical treatment of oral anticoagulants[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2019; 19(3): 166-171.
References:
1. LI Haigang,FAN Rong,MA Ning,et al.Research progress on pharmacokinetic factors of warfarin[J].Chin J Clin Pharmacol Ther,2017,22(11):1292-1298.In Chinese with English abstract.
2. SHU Changcheng,HOU Zhenshi.Research progress of new oral anticoagulants in the treatment of patients with atrial fibrillation[J].China Mod Med,2019,26(4):26-28.In Chinese with English abstract.
3. Verhoef T I,Redekop W K,Daly A K,et al.Pharmacogenetic-guided dosing of coumarin anticoagulants:algorithms for warfarin,acenocoumarol and phenprocoumon[J].Br J Clin Pharmacol,2014,77(4):626-641.
4. XIANG Haiyan,TANG Yanhua.Overview of clinical application of warfarin anticoagulant therapy[J].Chongqing Med J,2012,41(16):1652-1654.In Chinese.
5. Cardiology Branch of Chinese Medical Association,Cardiovascular and Cerebrovascular Diseases Committee of the Chinese Gerontological Society.Chinese expert consensus on warfarin anticoagulant therapy[J].Chin J Intern Med,2013,52(1):76-82.In Chinese.
6. KANG Junping.Key points in clinical application of warfarin[J].Chin J Med,2014,49(1):11-14.In Chinese.
7. Flora D R,Rettie A E,Brundage R C,et al.CYP2C9 genotype-dependent warfarin pharmacokinetics:impact of CYP2C9 genotype on R- and S-warfarin and their oxidative metabolites[J].J Clin Pharmacol,2017,57(3):382-393.
8. Kaye J B,Schultz L E,Steiner H E,et al.Warfarin pharmacogenomics in diverse populations[J].Pharmacotherapy,2017,37(9):1150-1163.
9. Gemmati D,Burini F,Talarico A,et al.The active metabolite of warfarin (3′-hydroxywarfarin) and correlation with INR,warfarin and drug weekly dosage in patients under oral anticoagulant therapy:a pharmacogenetics study[J].PLoS One,2016,11(9):e0162084.
10. Ray W A,Chung C P,Murray K T,et al.Association of proton pump inhibitors with reduced risk of warfarin-related serious upper gastrointestinal bleeding[J].Gastroenterology,2016,151(6):1105-1112.
11. Johnson J A,Caudle K E,GONG Li,et al.Clinical pharmacogenetics implementation consortium(CPIC) guidelines for pharmacogenetics-guided warfarin dosing:2017 update[J].Clin Pharmacol Ther,2017,102(3):397-404.
12. Shaw K,Amstutz U,Kim R B,et al.Clinical practice recommendations on genetic testing of CYP2C9 and VKORC1 variants in warfarin therapy[J].Ther Drug Monit,2015,37(4):428-436.
13. Shaw K,Amstutz U,Hildebrand C,et al.VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children[J].Pediatr Blood Cancer,2014,61(6):1055-1062.
14. WEI Meng,YE Fei,XIE Dujiang,et al.A new algorithm to predict warfarin dose from polymorphisms of CYP4F2,CYP2C9 and VKORC1 and clinical variables:derivation in Han Chinese patients with non valvular atrial fibrillation[J].Thromb Haemost,2012,107(6):1083-1091.
15. Fenger-Eriksen C,Münster A M,Grove E L.New oral anticoagulants:clinical indications,monitoring and treatment of acute bleeding complications[J].Acta Anaesthesiol Scand,2014,58(6):651-659.
16. DOU Liwen,GAO Weibo,ZHU Jihong.Emergency application guidance of novel oral anticoagulants[J].Chin Gen Pract,2017,20(23):2900-2905.In Chinese with English abstract.
17. ZHOU Jianguang,ZHOU Yingqi.Characteristics and clinical research of new oral anticoagulants[J].Clin Med J,2013,11(5):8-14.In Chinese with English abstract.
18. WANG Bing,LIU Ying,LIU Dengke,et al.Direct factor Ⅹa inhibitor betrixaban[J].Drugs Clin,2015,30(2):217-221.In Chinese with English abstract.
19. Huisman M V,Klok F A.Pharmacological properties of betrixaban[J].Eur Heart J Suppl,2018,20(Suppl E):E12-E15.
20. Stangier J.Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate[J].Clin Pharmacokinet,2008,47(5):285-295.
21. Hankey G J,Eikelboom J W.Dabigatran etexilate:a new oral thrombin inhibitor[J].Circulation,2011,123(13):1436-1450.
22. Deftereos S,Anatoliotakis N,Giannopoulos G,et al.Novel direct factor Ⅱa and Ⅹa inhibitors:mechanisms of action and preclinical studies[J].Curr Clin Pharmacol,2012,7(3):149-165.
23. Patel M R,Mahaffey K W,Garg J,et al.Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J].N Engl J Med,2011,365(10):883-891.
24. Sherwood M W,Nessel C C,Hellkamp A S,et al.Gastrointestinal bleeding in patients with atrial fibrillation treated with rivaroxaban or warfarin:ROCKET AF trial[J].J Am Coll Cardiol,2015,66(21):2271-2281.
25. The EINSTEIN-PE investigators,Buller H R,Prins M H,et al.Oral rivaroxaban for the treatment of symptomatic pulmonary embolism[J].N Engl J Med,2012,366(14):1287-1297.
26. Granger C B,Alexander J H,McMurray J J V,et al.Apixaban versus warfarin in patients with atrial fibrillation[J].N Engl J Med,2011,365(11):981-992.
27. Schafer J H,Casey A L,Dupre K A,et al.Safety and efficacy of apixaban versus warfarin in patients with advanced chronic kidney disease[J].Ann Pharmacother,2018,52(11):1078-1084.
28. The Hokusai-VTE investigators,Buller H R,Décousus H,et al.Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism[J].N Engl J Med,2013,369(15):1406-1415.
29. Giugliano R P,Ruff C T,Braunwald E,et al.Edoxaban versus warfarin in patients with atrial fibrillation[J].N Engl J Med,2013,369(22):2093-2104.
30. Beyer-Westendorf J,Verhamme P,Bauersachs R.Betrixaban for prevention of venous thromboembolism in acute medically ill patients[J].Eur Heart J Suppl,2018,20(Suppl E):E16-E22.
31. Gibson C M,Korjian S,Chi G,et al.Comparison of fatal or irreversible events with extended-duration betrixaban versus standard dose enoxaparin in acutely ill medical patients:an APEX trial substudy[J].J Am Heart Assoc,2017,6(7):e006015.
32. Cohen A T,Harrington R A,Goldhaber S Z,et al.Extended thromboprophylaxis with betrixaban in acutely ill medical patients[J].N Engl J Med,2016,375(6):534-544.
33. Yee M K,Nafee T,Daaboul Y,et al.Increased benefit of betrixaban among patients with a history of venous thromboembolism:a post-hoc analysis of the APEX trial[J].J Thromb Thrombolysis,2017,45(1):1-8.
34. Connolly S J,Ezekowitz M D,Yusuf S,et al.Dabigatran versus warfarin in patients with atrial fibrillation[J].N Engl J Med,2009,361(12):1139-1151.
35. Schulman S,Kearon C,Kakkar A K,et al.Dabigatran versus warfarin in the treatment of acute venous thromboembolism[J].N Engl J Med,2009,361(24):2342-2352.
36. TANG Jie,PENG Jiahui,ZHANG Mengyuan,et al.Research progress of specific antagonists for new oral anticoagulants[J].Chin J Clin Healthc,2019,22(1):130-134.In Chinese with English abstract.
37. LIU Xiao,HONG Kui.Therapeutic strategies and specific antagonists of novel oral anticoagulant-related bleeding[J].Chin J Cardiol,2016,44(11):921-924.In Chinese.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口